Table 3. Effectiveness of qHPV vaccination in women 24 to 45 years of age against HPV 31/33/35/39/45/51/52/56/58/59-related CIN or condyloma (cumulative incidence, day 1 to year 6 in the EVG FAS population).

	Early Vaccination Group (N = 1,910)
Endpoint	n	Cases	PYR	Rate	95% CI
HPV 31/33/35/39/45/51/52/56/58/59-Related CIN or Condyloma	1,910	93	8,403.7	1.1	(0.9, 1.4)
By HPV Type
HPV 31-Related CIN or Condyloma	1,910	16	8,678.1	0.2	(0.1, 0.3)
HPV 33-Related CIN or Condyloma	1,910	7	8,711.7	0.1	(0.0, 0.2)
HPV 35-Related CIN or Condyloma	1,910	4	8,717.4	0.0	(0.0, 0.1)
HPV 39-Related CIN or Condyloma	1,910	17	8,668.3	0.2	(0.1, 0.3)
HPV 45-Related CIN or Condyloma	1,910	5	8,720.4	0.1	(0.0, 0.1)
HPV 51-Related CIN or Condyloma	1,910	17	8,686.5	0.2	(0.1, 0.3)
HPV 52-Related CIN or Condyloma	1,910	13	8,698.5	0.1	(0.1, 0.3)
HPV 56-Related CIN or Condyloma	1,910	23	8,654.5	0.3	(0.2, 0.4)
HPV 58-Related CIN or Condyloma	1,910	17	8,664.4	0.2	(0.1, 0.3)
HPV 59-Related CIN or Condyloma	1,910	6	8,712.4	0.1	(0.0, 0.1)
HPV 31/33/35/39/45/51/52/56/58/59-Related CIN or Condyloma	1,910	93	8,403.7	1.1	(0.9, 1.4)
By Endpoint Type
CIN (any grade)	1,909	93	8,191.1	1.1	(0.9, 1.4)
CIN 1	1,909	72	8,210.3	0.9	(0.7, 1.1)
CIN 2 or worse	1,909	40	8,296.4	0.5	(0.3, 0.7)
CIN 2	1,909	28	8,302.2	0.3	(0.2, 0.5)
CIN 3	1,909	23	8,311.0	0.3	(0.2, 0.4)
AIS	1,909	0	8,319.2	0.0	(0.0, 0.0)
Cervical Cancer	1,909	0	8,319.2	0.0	(0.0, 0.0)
Condyloma	1,910	0	8,721.0	0.0	(0.0, 0.0)

N = Number of subjects in the indicated group who received at least 1 dose of the qHPV vaccine.

n = Number of subjects in the indicated analysis population.

PYR = person years at risk; Rate = rate per 100 person years at risk; AIS = Adenocarcinoma in situ; CI = Confidence interval; CIN = Cervical intraepithelial neoplasia; HPV = Human papillomavirus; qHPV = Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine.